Opdivo plus AVD showed superior PFS and EFS compared to Adcetris plus AVD in patients with advanced Hodgkin lymphoma. The Opdivo regimen had a better side effect profile, with fewer severe side ...

Opdivo reduces the risk of death by 24% overall and 44% in patients with PD-L1 expression ≥1%, compared to placebo. Treatment-related side effects are more common with Opdivo, but no new safety ...

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The phase 3 CheckMate 816 study of Bri ...

Opdivo (nivolumab) is a brand-name intravenous (IV) infusion prescribed for certain cancers. The cost of the drug, with and without insurance, can depend on several factors, such as whether Opdivo ...

Rare side effects including thyroid problems or pancreatitis ... He is testing whether advanced melanoma patients can ...